Psychological Well-Being of Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab: 28-Week Interim Results from a Multicenter Observational Study in Italy Using the DASS-21 Questionnaire, the BLUE StudyE. Trovato, Antonio Costanzo, Claudio Bonifati et al.|Dermatology and Therapy|2026Cited by 1
Superior Clinical and Economic Value of <scp>IL</scp> ‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque PsoriasisGennaro Marco Falco, Ketty Peris, Clara De Simone et al.|International Journal of Dermatology|2026Cited by 1